Up to $30m funding will be provided to advance an innovative vaccine technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.
Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection
Ganguly will execute company's strategic focus on leveraging CustomGlycan to develop novel therapeutics
C2i Genomics expands its global reach and brings the first whole-genome sequencing minimal residual disease test to India
This new fund is amongst the largest for the sector in India
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
Company announced that it is accelerating its investment in its Leaps by Bayer impact investment unit with more than 1.3 billion euros funding until end of 2024
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
ChipCytometry delivers single-cell targeted spatial proteomics for complex whole-tissue analysis of the tumour microenvironment, as well as deep immune profiling for applications in immunology, neuroscience, and infectious disease
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Subscribe To Our Newsletter & Stay Updated
